© 2012 Wichtig Editore - ISSN 0391-5603 DOI:10.5301/RU.2012.9189 Urologia ( 2012 ; : 2) 142- 148 79 142 La risposta immunitaria Th1 mediata nella terapia della neoplasia vescicale non muscolo invasiva: il ruolo di HP-NAP Daniele D’Agostino 1 , Marco Racioppi 1 , Alessio Filianoti 1 , Luca Di Gianfrancesco 1 , Gaia Codolo 2-6 , Matteo Fassan 3 , Fabio Munari 2-5 , Massimo Rugge 3 , Mario Milco D’Elios 4 , Marina de Bernard 2-6 , Francesco Pagano 2 , PieFrancesco Bassi 1-2 1 Clinica Urologica, Università Cattolica del Sacro Cuore, Roma - Italy 2 Istituto Veneto di Medicina Molecolare, Padova - Italy 3 Istituto Oncologico Veneto IOV. Padova - Italy 4 Dipartimento di Medicina Interna, Università di Firenze - Italy 5 Dipartimento di Scienze biomediche, Università di Padova - Italy 6 Dipartimento di Biologia, Università di Padova - Italy Therapy for non-muscle invasive bladder cancer: HP-NAP PURPOSE: Patients with non-muscle invasive bladder cancer recurrence after 2 induction courses of BCG are eligible for radical cystectomy. So, in the last years research to discover new drugs for the manage- ment of non-muscle invasive bladder cancer recurrence after failure of first and second line therapy is ongoing. In accordance to the results obtained with BCG, whose mechanism depends on the induction of the T helper 1 (TH1) immune response, we investigated the activity of a Toll-like receptor (TLR) 2 li- gand, named Helicobacter Pylori Neutrophil Activating Protein (HP-NAP), that we recently demonstrated being able of enhancing the differentiation of Th1 cells, both in vitro and in vivo, because of its ability to create an IL-12 enriched milieu. MATERIALS AND METHODS: We show here, in a mouse model of bladder neoplasm implants, that local administration of HP-NAP decreases tumor growth by inducing tumor necrosis. RESULTS: The result is joined up with a massive cluster of both CD4 + and CD8 + IFN-γ + cells, within neoplasm and regional lymph nodes. It is of note that HP-NAP-treated tumors show also a reduced vascularization due to the anti-angiogenic activity of IFN-γ induced by HP-NAP. CONCLUSIONS: The present study suggests that the activity of HP-NAP against urothelial tumor burden warrants subsequent in vivo studies. KEY WORDS: Non-muscle invasive bladder cancer, Immunotherapy, HP-NAP; BCG PAROLE CHIAVE: Neoplasia vescicale non muscolo invasiva, immunoterapia, HP-NAP; BCG Accepted: February 15, 2012 ORIGINAL ARTICLE SINOSSI Il trattamento primario della neoplasia vescicale non musco- lo infiltrante è rappresentato dalla resezione transuretrale seguita da chemio od immunoterapia endovescicale. Il Ba- cillo di Calmette-Guérin (BCG) è tutt’ora il trattamento gold standard per la neoplasia vescicale non muscolo invasiva ad alto rischio di recidiva e progressione. L’immunoterapia PROGETTO DIAMANTE for personal use only for personal use only